Welcome to our dedicated page for Globus Med news (Ticker: GMED), a resource for investors and traders seeking the latest updates and insights on Globus Med stock.
Globus Medical, Inc. (NYSE: GMED) is a global musculoskeletal company in the surgical and medical instrument manufacturing industry. The GMED news page on Stock Titan aggregates coverage focused on the company’s musculoskeletal solutions, enabling technologies, and corporate developments that matter to investors and healthcare professionals.
News about Globus Medical often centers on quarterly and annual financial results, where the company reports worldwide net sales, U.S. and international performance, and non-GAAP metrics such as adjusted EBITDA, non-GAAP net income, and non-GAAP diluted earnings per share. These releases also discuss trends in its U.S. Spine business, contributions from acquisitions such as NuVasive and Nevro, and updates to revenue and earnings guidance.
Product and technology announcements are another key news category. Globus Medical has highlighted launches like the ANTHEM™ Elbow Fracture System within its trauma portfolio and additions to its Power Portfolio, including the DuraPro™ oscillating system with navigation and the Verzera™ high-speed drill system, which integrate with platforms such as ExcelsiusGPS™ and ExcelsiusHub™. These updates provide insight into the company’s efforts to advance spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies.
Investors can also follow corporate and legal developments, including leadership transitions at the executive level, share repurchase authorizations, and patent litigation outcomes related to expandable spinal fusion implants and other technologies. Earnings call schedules and webcast details are regularly announced, giving context on how management views business performance and strategic priorities.
By monitoring GMED news, readers can track how Globus Medical’s financial results, product pipeline, acquisitions, and intellectual property strategy evolve over time. Bookmark this page to access an organized stream of company-specific headlines and updates.
Summary not available.
Summary not available.
Summary not available.
Globus Medical (NYSE: GMED) will announce its Q1 2023 financial results on May 4, 2023, after market close. A teleconference is scheduled for the same day at 4:30 p.m. ET, allowing investors to discuss the results. The conference call will be streamed live via the company's website. Participants can also join via telephone by registering for the event. Globus Medical specializes in musculoskeletal solutions and was founded in 2003. The company emphasizes its dedication to product innovation for surgeon-assisted healing. A recording of the call will be available on the investor page following the event. For further information, details are accessible on the company’s website.
Globus Medical (NYSE: GMED) announced its financial results for Q4 and full year 2022, reporting worldwide net sales of $274.5 million for Q4, a 9.8% increase year-over-year, and $1,022.8 million for the full year, a 6.8% rise. GAAP net income for Q4 soared to $50.1 million, a 231.4% increase from the prior year, while diluted EPS was $0.49. The company achieved non-GAAP diluted EPS of $0.59. Free cash flow for 2022 reached $104.4 million, with no debt reported. Looking ahead, Globus forecasts 2023 net sales of $1.1 billion and non-GAAP diluted EPS of $2.30.
The merger between Globus Medical (GMED) and NuVasive (NUVA) will form a leading musculoskeletal technology company, enhancing innovation in patient care. Under the all-stock agreement, NuVasive shareholders will receive 0.75 shares of Globus Medical for each share held, implying a price of $57.72 and an equity value of $3.1 billion. The new entity aims to capitalize on a $50 billion market, with combined net sales growth projected at 6-8% for 2023. This transaction is expected to close mid-2023, pending regulatory and shareholder approval.
Globus Medical (NYSE:GMED) will announce its financial results for Q4 and full year ended December 31, 2022, after market close on February 21, 2023. Investors can access the release on the company's website. A teleconference will be held at 4:30 p.m. ET to discuss the results, with live access available through the Investors page. Participants can join via telephone after pre-registration. Globus Medical is recognized for its musculoskeletal solutions, focused on enhancing surgical outcomes. Further information about their products and initiatives can be found on their website.
Globus Medical, a leader in musculoskeletal solutions, reported Q3 2022 financial results with worldwide net sales of $254.1 million, marking a 10.6% increase year-over-year. U.S. net sales rose by 9.5%, and international sales surged by 17.7%. GAAP net income was $47.4 million, a 0.5% increase, with diluted EPS at $0.47. The company reaffirmed its full-year guidance of $1.025 billion in sales but lowered non-GAAP diluted EPS guidance to $2.03 due to unfavorable currency impacts. The company remains debt-free.
Globus Medical (NYSE:GMED) will announce its Q3 2022 financial results on November 8, 2022, after market close. A teleconference is scheduled for the same day at 4:30 PM ET, accessible via the company's investor website. This release will provide insights into the company's financial performance for the quarter ending September 30, 2022. Shareholders can listen to the live call and will have access to an audio archive afterward. For more details, visit the Globus Medical investor page.
Globus Medical reported its Q2 2022 financial results, achieving worldwide net sales of $263.6 million, a 5.0% increase year-over-year, with a 6.5% rise on a constant currency basis. GAAP net income rose to $54.6 million, a 31.4% increase from Q2 2021, with diluted EPS at $0.53. Notably, the Enabling Technologies sector saw a 41.7% growth to $29.4 million, fueled by strong demand for robotic systems. The company reaffirms its 2022 guidance of $1.025 billion in net sales and $2.10 non-GAAP diluted EPS.